In the present investigation, we demonstrated that alpelisib synergizes with mTOR or CDK4/6 inhibitors to induce HCC regression in vivo, supporting the further testing of these combination therapies for the treatment of HCCs carrying GOF PIK3CA mutations. The gene discussed is PIK3CA; the disease is hepatocellular carcinoma.